NCT00653406View on ClinicalTrials.gov

A Pharmacokinetic and Safety Study of Risperidone Long Acting Injectable in Schizophrenic Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

November 30, 2002

Study Completion Date

October 31, 2003

Conditions
Schizophrenia
Interventions
DRUG

Risperidone long acting injectable

Sponsors
All Listed Sponsors
lead

Janssen Pharmaceutical K.K.

INDUSTRY